;PMID: 11901090
;source_file_655.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..187] = [t:47..187]
;2)section:[e:191..221] = [t:191..221]
;3)section:[e:225..354] = [t:225..354]
;4)sentence:[e:358..492] = [t:358..492]
;5)sentence:[e:493..611] = [t:493..611]
;6)sentence:[e:612..958] = [t:612..958]
;7)sentence:[e:960..1077] = [t:960..1077]
;8)sentence:[e:1078..1197] = [t:1078..1197]
;9)sentence:[e:1198..1288] = [t:1198..1288]
;10)sentence:[e:1289..1413] = [t:1289..1413]
;11)sentence:[e:1414..1627] = [t:1414..1627]
;12)sentence:[e:1628..1744] = [t:1628..1744]
;13)sentence:[e:1745..2054] = [t:1745..2054]
;14)section:[e:2058..2103] = [t:2058..2103]
;Token/POS Errors
;ERROR_POS mismatch [31..32] t:token e:CD 4

;section 0 Span:0..41
;Drug Metab Dispos. 2002 Apr;30(4):378-84.
(SEC
  (FRAG (NNP:[0..4] Drug) (NNP:[5..10] Metab) (NNP:[11..17] Dispos)
        (.:[17..18] .) ('':[19..23] 2002) (DT:[24..29] Apr;3) (FW:[29..30] 0)
        (-LRB-:[30..31] -LRB-) (token:[31..32] 4) (-RRB-:[32..33] -RRB-)
        (::[33..34] :) (CD:[34..36] 37) (CD:[36..40] 8-84) (.:[40..41] .)))

;sentence 1 Span:47..187
;In vitro effect of standardized ginseng extracts and individual ginsenosides
;on  the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1.
;[79..95]:substance:"ginseng extracts"
;[111..123]:substance:"ginsenosides"
;[160..166]:cyp450:"CYP1A1"
;[168..174]:cyp450:"CYP1A2"
;[180..186]:cyp450:"CYP1B1"
(SENT
  (NP-HLN
    (NP
      (ADJP (FW:[47..49] In) (FW:[50..55] vitro))
      (NN:[56..62] effect))
    (PP (IN:[63..65] of)
      (NP
        (NP (JJ:[66..78] standardized)
           (NN:[79..86] ginseng) (NNS:[87..95] extracts))
        (CC:[96..99] and)
        (NP (JJ:[100..110] individual) (NNS:[111..123] ginsenosides))))
    (PP (IN:[124..126] on)
      (NP
        (NP (DT:[128..131] the) (JJ:[132..141] catalytic)
            (NN:[142..150] activity))
        (PP (IN:[151..153] of)
          (NP
            (NP
              (ADJP-1 (JJ:[154..159] human))
              (NN:[160..166] CYP1A1))
            (,:[166..167] ,)
            (NP
              (ADJP-1 (-NONE-:[167..167] *P*))
              (NN:[168..174] CYP1A2))
            (,:[174..175] ,) (CC:[176..179] and)
            (NP
              (ADJP-1 (-NONE-:[179..179] *P*))
              (NN:[180..186] CYP1B1))))))
    (.:[186..187] .)))

;section 2 Span:191..221
;Chang TK, Chen J, Benetton SA.
(SEC
  (FRAG (NNP:[191..196] Chang) (NNP:[197..199] TK) (,:[199..200] ,)
        (NNP:[201..205] Chen) (NNP:[206..208] J,) (NNP:[209..217] Benetton)
        (NNP:[218..220] SA) (.:[220..221] .)))

;section 3 Span:225..354
;Faculty of Pharmaceutical Sciences, The University of British Columbia, 
;Vancouver, British Columbia, Canada. tchang@unixg.ubc.ca
(SEC
  (FRAG (IN:[225..232] Faculty) (IN:[233..235] of)
        (NNP:[236..250] Pharmaceutical) (NNPS:[251..259] Sciences)
        (,:[259..260] ,) (DT:[261..264] The) (NNP:[265..275] University)
        (IN:[276..278] of) (NNP:[279..286] British) (NNP:[287..295] Columbia)
        (,:[295..296] ,) (NNP:[298..307] Vancouver) (,:[307..308] ,)
        (NNP:[309..316] British) (NNP:[317..325] Columbia) (,:[325..326] ,)
        (NNP:[327..333] Canada) (.:[333..334] .) (``:[335..347] tchang@unixg)
        (NN:[347..354] .ubc.ca)))

;sentence 4 Span:358..492
;Ginseng extract has been reported to decrease the incidence of 
;7,12-dimethylbenz[a]anthracene (DMBA)-initiated tumorigenesis in mice.
;[358..373]:substance:"Ginseng extract"
;[422..452]:substance:"7,12-dimethylbenz[a]anthracene"
;[454..458]:substance:"DMBA"
(SENT
  (S
    (NP-SBJ-1 (NN:[358..365] Ginseng) (NN:[366..373] extract))
    (VP (VBZ:[374..377] has)
      (VP (VBN:[378..382] been)
        (VP (VBN:[383..391] reported)
          (S
            (NP-SBJ-1 (-NONE-:[391..391] *))
            (VP (TO:[392..394] to)
              (VP (VB:[395..403] decrease)
                (NP
                  (NP (DT:[404..407] the) (NN:[408..417] incidence))
                  (PP (IN:[418..420] of)
                    (NP
                      (ADJP
                        (NML
                          (NML
                               (NN:[422..452] 7,12-dimethylbenz-LSB-a-RSB-anthracene))
                          (NML (-LRB-:[453..454] -LRB-) (NN:[454..458] DMBA)
                               (-RRB-:[458..459] -RRB-)))
                        (HYPH:[459..460] -) (VBN:[460..469] initiated))
                      (NN:[470..483] tumorigenesis))))
                (PP-LOC (IN:[484..486] in)
                  (NP (NNS:[487..491] mice)))))))))
    (.:[491..492] .)))

;sentence 5 Span:493..611
;A  potential mechanism for this effect by ginseng is inhibition of 
;DMBA-bioactivating cytochrome P450 (P450) enzymes.
;[535..542]:substance:"ginseng"
;[561..565]:substance:"DMBA"
;[580..610]:cyp450:"cytochrome P450 (P450) enzymes"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[493..494] A) (JJ:[496..505] potential) (NN:[506..515] mechanism))
      (PP (IN:[516..519] for)
        (NP
          (NP (DT:[520..524] this) (NN:[525..531] effect))
          (PP (IN:[532..534] by)
            (NP (NN:[535..542] ginseng))))))
    (VP (VBZ:[543..545] is)
      (NP-PRD
        (NP (NN:[546..556] inhibition))
        (PP (IN:[557..559] of)
          (NP
            (ADJP (NN:[561..565] DMBA) (HYPH:[565..566] -)
                  (VBG:[566..579] bioactivating))
            
            (NML
              (NML (NN:[580..590] cytochrome) (NN:[591..595] P450))
              (NML (-LRB-:[596..597] -LRB-) (NN:[597..601] P450)
                   (-RRB-:[601..602] -RRB-)))
            (NNS:[603..610] enzymes)))))
    (.:[610..611] .)))

;sentence 6 Span:612..958
;In the present in vitro  study, we examined the effect of a standardized
;Panax ginseng (or Asian ginseng)  extract (G115), a standardized Panax
;quinquefolius (or North American ginseng)  extract (NAGE), and individual
;ginsenosides (Rb1, Rb2, Rc, Rd, Re, Rf, and Rg1)  on CYP1 catalytic
;activities, as assessed by 7-ethoxyresorufin O-dealkylation.
;[685..698]:substance:"Panax ginseng"
;[703..716]:substance:"Asian ginseng"
;[719..726]:substance:"extract"
;[728..732]:substance:"G115"
;[750..769]:substance:"Panax quinquefolius"
;[774..796]:substance:"North American ginseng"
;[799..806]:substance:"extract"
;[808..812]:substance:"NAGE"
;[830..842]:substance:"ginsenosides"
;[844..847]:substance:"Rb1"
;[849..852]:substance:"Rb2"
;[854..856]:substance:"Rc"
;[858..860]:substance:"Rd"
;[862..864]:substance:"Re"
;[866..868]:substance:"Rf"
;[874..877]:substance:"Rg1"
;[883..887]:cyp450:"CYP1"
;[925..942]:substance:"7-ethoxyresorufin"
(SENT
  (S
    (PP (IN:[612..614] In)
      (NP (DT:[615..618] the) (JJ:[619..626] present)
        (ADJP (FW:[627..629] in) (FW:[630..635] vitro))
        (NN:[637..642] study)))
    (,:[642..643] ,)
    (NP-SBJ (PRP:[644..646] we))
    (VP (VBD:[647..655] examined)
      (NP
        (NP (DT:[656..659] the) (NN:[660..666] effect))
        (PP (IN:[667..669] of)
          (NP
            (NP
              (NP (DT:[670..671] a) (JJ:[672..684] standardized)
                (NML
                   (NN:[685..690] Panax) (NN:[691..698] ginseng)
                  (PRN (-LRB-:[699..700] -LRB-)
                    (FRAG (CC:[700..702] or)
                      (NP (JJ:[703..708] Asian) (NN:[709..716] ginseng)))
                    (-RRB-:[716..717] -RRB-)))
                (NN:[719..726] extract))
              (NP (-LRB-:[727..728] -LRB-) (NN:[728..732] G115)
                  (-RRB-:[732..733] -RRB-)))
            (,:[733..734] ,)
            (NP
              (NP (DT:[735..736] a) (JJ:[737..749] standardized)
                (NML
                   (NN:[750..755] Panax) (NN:[756..769] quinquefolius)
                  (PRN (-LRB-:[770..771] -LRB-)
                    (FRAG (CC:[771..773] or)
                      (NP (JJ:[774..779] North) (JJ:[780..788] American)
                          (NN:[789..796] ginseng)))
                    (-RRB-:[796..797] -RRB-)))
                (NN:[799..806] extract))
              (NP (-LRB-:[807..808] -LRB-) (NN:[808..812] NAGE)
                  (-RRB-:[812..813] -RRB-)))
            (,:[813..814] ,) (CC:[815..818] and)
            (NP (JJ:[819..829] individual) (NNS:[830..842] ginsenosides)
              (PRN (-LRB-:[843..844] -LRB-)
                (NP (NN:[844..847] Rb1) (,:[847..848] ,) (NN:[849..852] Rb2)
                    (,:[852..853] ,) (NN:[854..856] Rc) (,:[856..857] ,)
                    (NN:[858..860] Rd) (,:[860..861] ,) (NN:[862..864] Re)
                    (,:[864..865] ,) (NN:[866..868] Rf) (,:[868..869] ,)
                    (CC:[870..873] and) (NN:[874..877] Rg1))
                (-RRB-:[877..878] -RRB-)))))
        (PP (IN:[880..882] on)
          (NP (NN:[883..887] CYP1) (JJ:[888..897] catalytic)
              (NNS:[898..908] activities))))
      (,:[908..909] ,)
      (SBAR-MNR (IN:[910..912] as)
        (S
          (NP-SBJ-1 (-NONE-:[912..912] *))
          (VP (VBN:[913..921] assessed)
            (NP-1 (-NONE-:[921..921] *))
            (PP-MNR (IN:[922..924] by)
              (NP (NN:[925..942] 7-ethoxyresorufin)
                  (NN:[943..957] O-dealkylation)))))))
    (.:[957..958] .)))

;sentence 7 Span:960..1077
;G115 and NAGE decreased human recombinant CYP1A1, CYP1A2, and CYP1B1
;activities  in a concentration-dependent manner.
;[960..964]:substance:"G115"
;[969..973]:substance:"NAGE"
;[1002..1008]:cyp450:"CYP1A1"
;[1010..1016]:cyp450:"CYP1A2"
;[1022..1028]:cyp450:"CYP1B1"
(SENT
  (S
    (NP-SBJ (NN:[960..964] G115) (CC:[965..968] and) (NN:[969..973] NAGE))
    (VP (VBD:[974..983] decreased)
      (NP
        (NP
          (ADJP-1 (JJ:[984..989] human) (JJ:[990..1001] recombinant))
          (NN:[1002..1008] CYP1A1)
          (NML-2 (-NONE-:[1008..1008] *P*)))
        (,:[1008..1009] ,)
        (NP
          (ADJP-1 (-NONE-:[1009..1009] *P*))
          (NN:[1010..1016] CYP1A2)
          (NML-2 (-NONE-:[1016..1016] *P*)))
        (,:[1016..1017] ,) (CC:[1018..1021] and)
        (NP
          (ADJP-1 (-NONE-:[1021..1021] *P*))
          (NN:[1022..1028] CYP1B1)
          (NML-2 (NNS:[1029..1039] activities))))
      (PP (IN:[1041..1043] in)
        (NP (DT:[1044..1045] a)
          (ADJP (NN:[1046..1059] concentration) (HYPH:[1059..1060] -)
                (JJ:[1060..1069] dependent))
          (NN:[1070..1076] manner))))
    (.:[1076..1077] .)))

;sentence 8 Span:1078..1197
;Except for the competitive inhibition of  CYP1A1 by G115, the mode of
;inhibition was the mixed-type in the other cases.
;[1120..1126]:cyp450:"CYP1A1"
;[1130..1134]:substance:"G115"
(SENT
  (S
    (PP (IN:[1078..1084] Except)
      (PP (IN:[1085..1088] for)
        (NP
          (NP (DT:[1089..1092] the) (JJ:[1093..1104] competitive)
              (NN:[1105..1115] inhibition))
          (PP (IN:[1116..1118] of)
            (NP (NN:[1120..1126] CYP1A1)))
          (PP (IN:[1127..1129] by)
            (NP (NN:[1130..1134] G115))))))
    (,:[1134..1135] ,)
    (NP-SBJ
      (NP (DT:[1136..1139] the) (NN:[1140..1144] mode))
      (PP (IN:[1145..1147] of)
        (NP (NN:[1148..1158] inhibition))))
    (VP (VBD:[1159..1162] was)
      (NP-PRD (DT:[1163..1166] the) (JJ:[1167..1177] mixed-type))
      (PP (IN:[1178..1180] in)
        (NP (DT:[1181..1184] the) (JJ:[1185..1190] other)
            (NNS:[1191..1196] cases))))
    (.:[1196..1197] .)))

;sentence 9 Span:1198..1288
;A  striking finding was that NAGE was 45-fold more potent than G115 in
;inhibiting  CYP1A2.
;[1227..1231]:substance:"NAGE"
;[1236..1243]:quantitative-value:"45-fold"
;[1261..1265]:substance:"G115"
;[1281..1287]:cyp450:"CYP1A2"
(SENT
  (S
    (NP-SBJ (DT:[1198..1199] A) (JJ:[1201..1209] striking)
            (NN:[1210..1217] finding))
    (VP (VBD:[1218..1221] was)
      (SBAR-PRD (IN:[1222..1226] that)
        (S
          (NP-SBJ (NN:[1227..1231] NAGE))
          (VP (VBD:[1232..1235] was)
            (ADJP-PRD
              (ADJP
                (QP (CD:[1236..1238] 45) (HYPH:[1238..1239] -)
                    (JJ:[1239..1243] fold))
                (RBR:[1244..1248] more) (JJ:[1249..1255] potent))
              (PP (IN:[1256..1260] than)
                (NP (NN:[1261..1265] G115))))
            (PP (IN:[1266..1268] in)
              (S-NOM
                (NP-SBJ (-NONE-:[1268..1268] *))
                (VP (VBG:[1269..1279] inhibiting)
                  (NP (NN:[1281..1287] CYP1A2)))))))))
    (.:[1287..1288] .)))

;sentence 10 Span:1289..1413
;Compared with G115, NAGE also preferentially inhibited 7-ethoxyresorufin 
;O-dealkylation activity in human liver microsomes.
;[1303..1307]:substance:"G115"
;[1309..1313]:substance:"NAGE"
;[1344..1361]:substance:"7-ethoxyresorufin"
(SENT
  (S
    (S-ADV
      (NP-SBJ-1 (-NONE-:[1289..1289] *))
      (VP (VBN:[1289..1297] Compared)
        (NP-1 (-NONE-:[1297..1297] *))
        (PP (IN:[1298..1302] with)
          (NP (NN:[1303..1307] G115)))))
    (,:[1307..1308] ,)
    (NP-SBJ (NN:[1309..1313] NAGE))
    (ADVP (RB:[1314..1318] also))
    (ADVP (RB:[1319..1333] preferentially))
    (VP (VBD:[1334..1343] inhibited)
      (NP (NN:[1344..1361] 7-ethoxyresorufin) (NN:[1363..1377] O-dealkylation)
          (NN:[1378..1386] activity))
      (PP-LOC (IN:[1387..1389] in)
        (NP (JJ:[1390..1395] human) (NN:[1396..1401] liver)
            (NNS:[1402..1412] microsomes))))
    (.:[1412..1413] .)))

;sentence 11 Span:1414..1627
;Rb1, Rb2, Rc, Rd, Re, Rf, and  Rg1, either individually or as a mixture and
;at the levels reflecting those  found in an inhibitory concentration (100
;microg/ml) of NAGE or G115, did not  influence CYP1 activities.
;[1414..1417]:substance:"Rb1"
;[1419..1422]:substance:"Rb2"
;[1424..1426]:substance:"Rc"
;[1428..1430]:substance:"Rd"
;[1432..1434]:substance:"Re"
;[1436..1438]:substance:"Rf"
;[1445..1448]:substance:"Rg1"
;[1534..1558]:quantitative-name:"inhibitory concentration"
;[1560..1563]:quantitative-value:"100"
;[1564..1573]:quantitative-units:"microg/ml"
;[1578..1582]:substance:"NAGE"
;[1586..1590]:substance:"G115"
;[1611..1615]:cyp450:"CYP1"
(SENT
  (S
    (NP-SBJ (NN:[1414..1417] Rb1) (,:[1417..1418] ,) (NN:[1419..1422] Rb2)
            (,:[1422..1423] ,) (NN:[1424..1426] Rc) (,:[1426..1427] ,)
            (NN:[1428..1430] Rd) (,:[1430..1431] ,) (NN:[1432..1434] Re)
            (,:[1434..1435] ,) (NN:[1436..1438] Rf) (,:[1438..1439] ,)
            (CC:[1440..1443] and) (NN:[1445..1448] Rg1))
    (,:[1448..1449] ,)
    (UCP-ADV
      (UCP (CC:[1450..1456] either)
        (ADVP (RB:[1457..1469] individually))
        (CC:[1470..1472] or)
        (PP (IN:[1473..1475] as)
          (NP (DT:[1476..1477] a) (NN:[1478..1485] mixture))))
      (CC:[1486..1489] and)
      (PP (IN:[1490..1492] at)
        (NP
          (NP (DT:[1493..1496] the) (NNS:[1497..1503] levels))
          (VP (VBG:[1504..1514] reflecting)
            (NP
              (NP (DT:[1515..1520] those))
              (VP (VBN:[1522..1527] found)
                (NP (-NONE-:[1527..1527] *))
                (PP (IN:[1528..1530] in)
                  (NP
                    (NP (DT:[1531..1533] an)
                       (JJ:[1534..1544] inhibitory)
                       (NN:[1545..1558] concentration)
                      (PRN (-LRB-:[1559..1560] -LRB-)
                        (NP
                          (NP (CD:[1560..1563] 100) (NN:[1564..1570] microg))
                          (PP (SYM:[1570..1571] /)
                            (NP (NN:[1571..1573] ml))))
                        (-RRB-:[1573..1574] -RRB-)))
                    (PP (IN:[1575..1577] of)
                      (NP (NN:[1578..1582] NAGE) (CC:[1583..1585] or)
                          (NN:[1586..1590] G115)))))))))))
    (,:[1590..1591] ,)
    (VP (VBD:[1592..1595] did) (RB:[1596..1599] not)
      (VP (VB:[1601..1610] influence)
        (NP (NN:[1611..1615] CYP1) (NNS:[1616..1626] activities))))
    (.:[1626..1627] .)))

;sentence 12 Span:1628..1744
;However, at a higher ginsenoside concentration (50  microg/ml), Rb1, Rb2, Rc,
;Rd, and Rf inhibited these activities.
;[1649..1660]:substance:"ginsenoside"
;[1676..1678]:quantitative-value:"50"
;[1680..1689]:quantitative-units:"microg/ml"
;[1692..1695]:substance:"Rb1"
;[1697..1700]:substance:"Rb2"
;[1702..1704]:substance:"Rc"
;[1706..1708]:substance:"Rd"
;[1714..1716]:substance:"Rf"
(SENT
  (S
    (ADVP (RB:[1628..1635] However))
    (,:[1635..1636] ,)
    (PP (IN:[1637..1639] at)
      (NP (DT:[1640..1641] a) (JJR:[1642..1648] higher)
          (NN:[1649..1660] ginsenoside) (NN:[1661..1674] concentration)
        (PRN (-LRB-:[1675..1676] -LRB-)
          (NP
            (NP (CD:[1676..1678] 50) (NN:[1680..1686] microg))
            (PP (SYM:[1686..1687] /)
              (NP (NN:[1687..1689] ml))))
          (-RRB-:[1689..1690] -RRB-))))
    (,:[1690..1691] ,)
    (NP-SBJ (NN:[1692..1695] Rb1) (,:[1695..1696] ,) (NN:[1697..1700] Rb2)
            (,:[1700..1701] ,) (NN:[1702..1704] Rc) (,:[1704..1705] ,)
            (NN:[1706..1708] Rd) (,:[1708..1709] ,) (CC:[1710..1713] and)
            (NN:[1714..1716] Rf))
    (VP (VBD:[1717..1726] inhibited)
      (NP (DT:[1727..1732] these) (NNS:[1733..1743] activities)))
    (.:[1743..1744] .)))

;sentence 13 Span:1745..2054
;Overall, our in  vitro findings indicate that standardized NAGE and G115
;extracts, which were not  treated with calf serum or subjected to acid
;hydrolysis, inhibited CYP1  catalytic activity in an enzyme-selective and
;extract-specific manner, but the  effects were not due to Rb1, Rb2, Rc, Rd,
;Re, Rf, or Rg1.
;[1804..1808]...[1818..1826]:substance:"NAGE"..."extracts"
;[1813..1826]:substance:"G115 extracts"
;[1884..1888]:substance:"acid"
;[1911..1915]:cyp450:"CYP1"
;[1942..1948]:substance:"enzyme"
;[1963..1970]:substance:"extract"
;[2021..2024]:substance:"Rb1"
;[2026..2029]:substance:"Rb2"
;[2031..2033]:substance:"Rc"
;[2035..2037]:substance:"Rd"
;[2039..2041]:substance:"Re"
;[2043..2045]:substance:"Rf"
;[2050..2053]:substance:"Rg1"
(SENT
  (S
    (ADVP (RB:[1745..1752] Overall))
    (,:[1752..1753] ,)
    (NP-SBJ (PRP$:[1754..1757] our)
      (ADJP (FW:[1758..1760] in) (FW:[1762..1767] vitro))
      (NNS:[1768..1776] findings))
    (VP (VBP:[1777..1785] indicate)
      (SBAR (IN:[1786..1790] that)
        (S
          (S
            (NP-SBJ
              (NP
                (NP
                  (ADJP-4 (JJ:[1791..1803] standardized))
                  (NN:[1804..1808] NAGE)
                  (NML-3 (-NONE-:[1808..1808] *P*)))
                (CC:[1809..1812] and)
                (NP
                  (ADJP-4 (-NONE-:[1812..1812] *P*))
                   (NN:[1813..1817] G115)
                  (NML-3 (NNS:[1818..1826] extracts))))
              (,:[1826..1827] ,)
              (SBAR
                (WHNP-2 (WDT:[1828..1833] which))
                (S
                  (NP-SBJ-2 (-NONE-:[1833..1833] *T*))
                  (VP (VBD:[1834..1838] were) (RB:[1839..1842] not)
                    (VP
                      (VP (VBN:[1844..1851] treated)
                        (NP-2 (-NONE-:[1851..1851] *))
                        (PP-CLR (IN:[1852..1856] with)
                          (NP (NN:[1857..1861] calf) (NN:[1862..1867] serum))))
                      (CC:[1868..1870] or)
                      (VP (VBN:[1871..1880] subjected)
                        (NP-2 (-NONE-:[1880..1880] *))
                        (PP-CLR (TO:[1881..1883] to)
                          (NP (NN:[1884..1888] acid)
                              (NN:[1889..1899] hydrolysis)))))))))
            (,:[1899..1900] ,)
            (VP (VBD:[1901..1910] inhibited)
              (NP (NN:[1911..1915] CYP1) (JJ:[1917..1926] catalytic)
                  (NN:[1927..1935] activity))
              (PP (IN:[1936..1938] in)
                (NP (DT:[1939..1941] an)
                  (NML
                    (NML
                      (ADJP (NN:[1942..1948] enzyme) (HYPH:[1948..1949] -)
                            (JJ:[1949..1958] selective))
                      (NML-1 (-NONE-:[1958..1958] *P*)))
                    (CC:[1959..1962] and)
                    (NML
                      (ADJP (NN:[1963..1970] extract) (HYPH:[1970..1971] -)
                            (JJ:[1971..1979] specific))
                      (NML-1 (NN:[1980..1986] manner))))))))
          (,:[1986..1987] ,) (CC:[1988..1991] but)
          (S
            (NP-SBJ (DT:[1992..1995] the) (NNS:[1997..2004] effects))
            (VP (VBD:[2005..2009] were) (RB:[2010..2013] not)
              (PP-PRD (JJ:[2014..2017] due)
                (PP (TO:[2018..2020] to)
                  (NP (NN:[2021..2024] Rb1) (,:[2024..2025] ,)
                      (NN:[2026..2029] Rb2) (,:[2029..2030] ,)
                      (NN:[2031..2033] Rc) (,:[2033..2034] ,)
                      (NN:[2035..2037] Rd) (,:[2037..2038] ,)
                      (NN:[2039..2041] Re) (,:[2041..2042] ,)
                      (NN:[2043..2045] Rf) (,:[2045..2046] ,)
                      (CC:[2047..2049] or) (NN:[2050..2053] Rg1)))))))))
    (.:[2053..2054] .)))

;section 14 Span:2058..2103
;PMID: 11901090 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2058..2062] PMID) (::[2062..2063] :) (CD:[2064..2072] 11901090)
        (NN:[2073..2074] -LSB-) (NNP:[2074..2080] PubMed) (::[2081..2082] -)
        (NN:[2083..2090] indexed) (IN:[2091..2094] for)
        (NNP:[2095..2103] MEDLINE-RSB-)))
